ClinicalTrials.gg

Program

Rifampin

Also written as “Rifampicin”, “rifampicin” and “RSS0343 Tablet; Rifampicin Capsules”.

Its studies are mostly in Neoplasms · Tuberculosis, Pulmonary · Hematologic Neoplasms · Melanoma · Bronchiectasis, led by 28 companies.

Furthest: phase 2, since Sep 25, 200745 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb40 open or runningphase 1since Sep 25, 2007Sep 25, 2007none ahead
AstraZeneca30 open or runningphase 1since Aug 23, 2013Aug 23, 2013none ahead
HUTCHMED30 open or runningphase 1since Aug 10, 2020Aug 10, 2020none ahead
Jiangsu HengRui Medicine32 open or runningphase 1since Jul 28, 2020Jul 28, 2020none ahead
Takeda30 open or runningphase 1since Jan 23, 2008Jan 23, 2008none ahead
Boehringer Ingelheim20 open or runningphase 1since Jun 20, 2014Jun 20, 2014none ahead
GlaxoSmithKline20 open or runningphase 2since May 16, 2022Sep 26, 2013none ahead
Hoffmann-La Roche20 open or runningphase 1since Jan 9, 2013Jan 9, 2013none ahead
Johnson & Johnson20 open or runningphase 1since Jan 23, 2012Jan 23, 2012none ahead
Pfizer20 open or runningphase 1since Oct 3, 2006Oct 3, 2006none ahead
PTC Therapeutics20 open or runningphase 1since Nov 4, 2014Nov 4, 2014none ahead
Bayer10 open or runningphase 1since Nov 4, 2016Nov 4, 2016none ahead
Beijing Aosaikang Pharmaceutical10 open or runningphase 1since Nov 11, 2022Nov 11, 2022none ahead
Betta Pharmaceuticals11 open or runningphase 1since Jul 1, 2024Jul 1, 2024none ahead
Eisai10 open or runningphase 1since Jan 23, 2014Jan 23, 2014none ahead
emalex-biosciences-inc10 open or runningphase 1since Dec 22, 2023Dec 22, 2023none ahead
f2g-biotech-gmbh10 open or runningphase 1since Nov 19, 2019Nov 19, 2019none ahead
Guangdong Zhongsheng Pharmaceutical10 open or runningphase 1since Sep 4, 2023Sep 4, 2023none ahead
Idorsia Pharmaceuticals10 open or runningphase 1since Jul 5, 2018Jul 5, 2018none ahead
Ipsen10 open or runningphase 1since Jul 29, 2020Jul 29, 2020none ahead
LG Chem10 open or runningphase 1since Aug 31, 2011Aug 31, 2011none ahead
phathom-pharmaceuticals-inc10 open or runningphase 1since Sep 15, 2020Sep 15, 2020none ahead
SecuraBio10 open or runningphase 1since Sep 18, 2013Sep 18, 2013none ahead
Sunshine Lake Pharma10 open or runningphase 1since Aug 31, 2021Aug 31, 2021none ahead
thirty-respiratory-limited10 open or runningphase 2since Aug 21, 2023Aug 21, 2023none ahead
tyk-medicines-inc10 open or runningphase 1since Jan 17, 2024Jan 17, 2024none ahead
vantia-ltd10 open or runningphase 1since May 7, 2015May 7, 2015none ahead
Vertex Pharmaceuticals10 open or runningphase 1since Nov 19, 2009Nov 19, 2009none ahead

Also a collaborator on its studies: cambridge-cognition-ltd, parexel, covance and pra-health-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 31 studies since Oct 3, 2006.

  1. Sep 15, 2020Phase 1 study in Drug Drug InteractionHUTCHMED · NCT04557397 · 28 enrolled · United States
  2. Jun 8, 2021Phase 1 study in Advanced Solid TumoursAstraZeneca · NCT04959266 · 5 enrolled · United States, Spain
  3. Aug 31, 2021Sunshine Lake Pharma's first study: phase 1 study in Healthy VolunteersNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05057949 · 32 enrolled · China
  4. Feb 10, 2022Phase 1 study in Healthy AdultsBristol-Myers Squibb · NCT05255276 · 36 enrolled · United States
  5. May 16, 2022Phase 2 study in TuberculosisGlaxoSmithKline · NCT05382312 · 127 enrolled · South Africa
  6. Oct 27, 2022Phase 1 study in RecurrenceHUTCHMED · NCT05602597 · 59 enrolled · United States
  7. Nov 11, 2022Beijing Aosaikang Pharmaceutical's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Beijing Aosaikang PharmaceuticalBeijing Aosaikang Pharmaceutical · NCT05631678 · 48 enrolled · China
  8. Aug 21, 2023thirty-respiratory-limited's first study: phase 2 study in Rifampicin Susceptible Pulmonary TuberculosisNew to thirty-respiratory-limitedthirty-respiratory-limited · NCT06041919 · 20 enrolled · South Africa
  9. Sep 4, 2023Guangdong Zhongsheng Pharmaceutical's first study: phase 1 study in Drug Drug InteractionNew to Guangdong Zhongsheng PharmaceuticalGuangdong Zhongsheng Pharmaceutical · NCT06031454 · 56 enrolled · China
  10. Dec 22, 2023emalex-biosciences-inc's first study: phase 1 study in Drug InteractionNew to emalex-biosciences-incemalex-biosciences-inc · NCT06194864 · 45 enrolled · Canada
  11. Jan 17, 2024tyk-medicines-inc's first study: phase 1 study in NSCLCNew to tyk-medicines-inctyk-medicines-inc · NCT06255951 · 48 enrolled · China
  12. Mar 22, 2024Phase 1 study in Renal Insufficiency, ChronicJiangsu HengRui Medicine · NCT06344936 · 28 planned · China
  13. Jul 1, 2024Betta Pharmaceuticals's first study: phase 1 study in HealthyNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT06492525 · 36 planned · China
  14. Jul 6, 2026Phase 1 study in Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary DiseaseJiangsu HengRui Medicine · NCT07696091 · 40 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule

Studies

All 45 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07696091Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease · China1Not yet recruitingJiangsu HengRui MedicineSep 202640
NCT06492525Healthy · China1Not yet recruitingBetta PharmaceuticalsOct 202436
NCT06344936Renal Insufficiency, Chronic · China1Not yet recruitingJiangsu HengRui MedicineJul 202428
NCT06255951NSCLC · China1Completedtyk-medicines-incMay 23, 202448
NCT06194864Drug Interaction · Canada1Completedemalex-biosciences-incMay 14, 202445
NCT06031454Drug Drug Interaction · China1CompletedGuangdong Zhongsheng PharmaceuticalNov 1, 202356
NCT06041919Rifampicin Susceptible Pulmonary Tuberculosis · South Africa2Terminatedthirty-respiratory-limitedJul 24, 202420
NCT05631678Carcinoma, Non-Small-Cell Lung · China1CompletedBeijing Aosaikang PharmaceuticalAug 3, 202248
NCT05602597Recurrence · United States1CompletedHUTCHMEDAug 6, 202259
NCT05382312Tuberculosis · South Africa2CompletedGlaxoSmithKlineMay 27, 2025127
NCT05255276Healthy Adults · United States1CompletedBristol-Myers SquibbMay 12, 202236
NCT05057949Healthy Volunteers · China1CompletedSunshine Lake PharmaFeb 17, 202232
NCT04959266Advanced Solid Tumours · United States, Spain1TerminatedAstraZenecaJun 1, 20225
NCT04558216Healthy Participants · United States1Withdrawnphathom-pharmaceuticals-incFeb 7, 20210
NCT04557397Drug Drug Interaction · United States1CompletedHUTCHMEDOct 18, 202028
NCT04510649Healthy · United States1CompletedHUTCHMEDSep 11, 202028
NCT04537715Hematologic Neoplasms · United States, Spain1CompletedIpsenApr 3, 202342
NCT04494659Healthy Adult Subjects · China1CompletedJiangsu HengRui MedicineAug 13, 202021
NCT04171739Healthy · United Kingdom1Completedf2g-biotech-gmbhFeb 11, 202024
NCT03596294Healthy Subjects · Netherlands1CompletedIdorsia PharmaceuticalsAug 3, 201814
NCT03486314Advanced Solid Neoplasm · United States1CompletedTakedaMay 10, 201920
NCT03307252Healthy · Germany1CompletedBoehringer IngelheimMay 2, 201845
NCT02975440Endometriosis · Germany1CompletedBayerJan 27, 201712
NCT02770222Healthy Subjects1CompletedJohnson & JohnsonJul 201640
NCT02608034Melanoma · United States, Israel, Korea, Republic of and more1CompletedHoffmann-La RocheSep 10, 201832
NCT02440841Nocturia · Germany1Completedvantia-ltdJul 201529
NCT02409004Healthy · Canada1CompletedPTC TherapeuticsMar 201515
NCT02286635Healthy Volunteers · United States1CompletedPTC TherapeuticsDec 201458
NCT02173717Healthy1CompletedBoehringer IngelheimJul 200924
NCT02046850Solid Tumours · United States1CompletedAstraZenecaApr 201424
NCT02055703Healthy Subjects · United States1CompletedEisaiApr 2014195
NCT01954043Neoplasms · United States, Australia, United Kingdom1CompletedGlaxoSmithKlineFeb 29, 201623
NCT01950364Hodgkin Disease · Belgium, Lithuania, Spain1CompletedTakedaOct 201420
NCT01947777Healthy · United States1CompletedSecuraBioNov 201314
NCT01929603Neoplasms · Belgium, Netherlands1CompletedAstraZenecaMay 201432
NCT01765543Melanoma · United States, Brazil, Croatia and more1CompletedHoffmann-La RocheNov 201527
NCT01655147Healthy · Belgium1CompletedJohnson & JohnsonMar 201219
NCT01426906Healthy Male Volunteers · Korea, Republic of1CompletedLG ChemMar 201124
NCT01324323Hematologic Neoplasms · United States, United Kingdom1CompletedBristol-Myers SquibbFeb 1, 201214
NCT01311505Tuberculosis · Philippines1CompletedPfizerMay 201121
NCT01018368Cystic Fibrosis · United States1CompletedVertex PharmaceuticalsMar 201024
NCT01002079Alzheimer Disease · India1CompletedBristol-Myers SquibbOct 201020
NCT00608907Multiple Myeloma · Israel, Italy, Poland and more1CompletedTakedaMar 201061
NCT00534807Neoplasms · United States1WithdrawnBristol-Myers SquibbNov 20080
NCT00384280Healthy1CompletedPfizerNov 200624

How it is read

Names in the registry

  • “Rifampin”, 18 entries
  • “Rifampicin”, 9 entries
  • “rifampicin”, 5 entries
  • “RSS0343 Tablet; Rifampicin Capsules”, 1 entry
  • “RIFAFOUR e-275”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.